Shanghai cell therapy research group

Shanghai Cell Therapy Group (SCTG) is a leading Chinese biotechnology company specializing in the development and commercialization of advanced cell therapies, particularly CAR-T and immune cell treatments for cancer. Founded in 2013 and headquartered in Shanghai, the company operates a comprehensive ecosystem that includes cell storage (biobanking), precision diagnosis, and clinical research. SCTG is unique for its integrated model, which includes its own affiliated hospital to facilitate rapid clinical translation of its pipeline. Their flagship "Baize Plan" aims to make cell therapy affordable and effective for a broad patient population over the next several decades. The company's R&D focus extends to both hematological malignancies and challenging solid tumors using non-viral vector technologies and nanobody-based CARs. With large-scale GMP manufacturing capabilities, SCTG is positioned as a major player in the global cell therapy landscape.